EGFR and non-small cell lung carcinoma: To the best of our knowledge, our retrospective study is the first to identify clinical aspects of serious hepatotoxicity related to osimertinib treatment immediately after nivolumab in patients with advanced NSCLC harboring the EGFR mutation.